Dynavax hepatitis C drug brings antiviral response in early-stage trial

01/26/2010 | Reuters

An early-stage study showed that high doses of Dynavax Technologies' hepatitis C drug reduced the severity of viral infection in patients who also received other antivirals. The treatment, SD-101, outperformed older drugs in stimulating the production of two forms of interferons, which help the immune system fight viruses and other pathogens.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ